H&R Block (HRB) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
29 Sep, 2026Executive summary
Fiscal 2026 saw 4.9% revenue growth, strong operating cash flow, and $714 million returned to shareholders via dividends and share repurchases.
Leadership transitioned from Jeff Jones to Curtis Campbell as President and CEO, with three new directors joining the board.
The board remains focused on strategic direction, talent development, and succession planning.
Voting matters and shareholder proposals
Shareholders will vote on electing nine directors, ratifying Deloitte & Touche LLP as auditor, advisory approval of executive compensation, and approval of the 2026 Long Term Incentive Plan.
The board recommends voting FOR all proposals.
Board of directors and corporate governance
Board size set at nine following retirements; four standing committees oversee audit, compensation, governance, and finance.
Board diversity includes 5 of 9 female nominees and 5 ethnically diverse members; average tenure is five years.
Annual board, committee, and director evaluations are conducted, with a substantial majority of directors deemed independent.
Mandatory director resignation policies and stock ownership guidelines are in place.
Latest events from H&R Block
- Director elections, auditor ratification, and executive pay up for virtual shareholder vote.HRB
Proxy filing - Revenue up 4.9%, net income up 20.8%, and dividend raised 10% with strong 2027 outlook.HRB
Q4 2026 - Q3 2026 delivered 5.3% revenue growth, higher profits, and raised full-year guidance.HRB
Q3 2026 - Steady growth, strong cash flow, and digital innovation fuel long-term value creation.HRB
Investor presentation - Q2 revenue up 11.1% year-over-year; full-year outlook and capital returns reaffirmed.HRB
Q2 2026 - Leadership transition, financial growth, and strong governance with a focus on ESG and pay-for-performance.HRB
Proxy Filing - Revenue up 5.4% year-over-year; net loss widened, but full-year outlook reaffirmed.HRB
Q1 2025 - Double-digit EPS growth, higher dividend, and robust FY25 outlook highlight strong performance.HRB
Q4 2024 - Q2 revenue flat, net loss widened, but FY25 outlook and capital returns reaffirmed.HRB
Q2 2025